top of page
JOINT PROJECTS
Laxxon Medical collaborates with industry leaders, research institutions, and public organizations to pioneer next-generation drug delivery solutions using our SPID®-Technology.
LXM-5: Levodopa + Carbidopa Treatment
Levodopa and Carbidopa formulated as 3D screen-printed tablet (3DSP dLD/CD) - 2024 INP 0136
LXM-5 is a next-generation treatment for Parkinson’s disease developed using Laxxon’s proprietary SPID®-Technology. This oral formulation enables precise, controlled drug release, enhancing bioavailability and patient compliance. The project has received funding support from ESF Plus and the Free State of Thuringia, recognizing its potential to significantly improve therapeutic outcomes for Parkinson’s patients.
.png)
LXM-2: Oral GLP-1 Agonist Therapy
Formulation of a 3D screen-printed tablet for oral administration of peptides using a GLP-1 receptor agonist in combination with a permeation enhancer as an example - 2024 INP 0153
LXM-2 is an innovative oral formulation of GLP-1 receptor agonists designed to treat type 2 diabetes and obesity. By leveraging Laxxon’s SPID®-Technology, this project aims to overcome limitations of injectable GLP-1 therapies, offering a more patient-friendly solution without compromising efficacy. The development has been funded by ESF Plus and the Free State of Thuringia, underscoring its clinical and societal relevance.
.png)
bottom of page